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Translational Relevance
The findings of STAND, a randomized, phase II, open-label trial that assessed the effect of treatment sequence with sipuleucel-T (an autologous cellular immunotherapy) and androgen deprivation therapy (ADT) on immune responses, may inform the design of future clinical trials and shape clinical practice across a broad spectrum of prostate cancer care. In biochemically-recurrent prostate cancer (BRPC) patients at high risk for metastasis in STAND, T cell immune responses were generally greater when sipuleucel-T was administered prior to ADT compared with the reverse sequence. Post-treatment, cellular and humoral responses against target antigens were increased significantly versus baseline and remained for 24 months (both arms). Further investigation is needed to determine if this sequence leads to improved clinical outcomes. However, in both BRPC and perhaps in advanced hormone-sensitive prostate cancer settings, future research on the combined use of immunotherapy and androgen-directed therapies may be optimized by sequencing sipuleucel-T prior to androgen deprivation. 
Introduction
Following primary treatment for localized prostate cancer, ∼20 to 40% of patients will develop biochemically-recurrent prostate cancer (BRPC) (1) . Many of these men will eventually develop metastatic progression, particularly those with a prostate-specific antigen doubling time (PSADT) <12 months (2) . Androgen deprivation therapy (ADT), commonly used to delay disease progression in men with BRPC (3), has not been shown to extend overall survival (4) . Hence, there remains a need to improve outcomes in these patients. ADT has been shown to augment antitumor immune responses in animal models (5-7) and in patients with prostate cancer (6, (8) (9) (10) , especially when combined with immunotherapies (11) . Several (but not all) studies have shown superior immunologic and antitumor responses when immunotherapy was administered prior to ADT (7, 12, 13) . However, while there is a clear rationale for combining ADT with immunological therapies in men with prostate cancer (14) , optimal sequencing remains unresolved.
Sipuleucel-T, an autologous cellular immunotherapy targeting prostatic acid phosphatase (PAP), is FDA-approved for treating asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC) (15) . In the phase III, IMPACT trial (NCT01133704), sipuleucel-T significantly reduced the risk of death by 22% versus control in men with mCRPC (16) . In localized prostate cancer, sipuleucel-T induces T cell and B cell trafficking to the tumor margin when administered prior to prostatectomy (17) . Sipuleucel-T also elicits sustained immune responses in patients with BRPC (18).
We conducted a randomized, phase II trial (STAND) combining ADT with sipuleucel-T (in alternate sequences) in patients with BRPC at high risk of metastatic 
Methods
Patients
Eligible men aged ≥18 years had confirmed prostatic adenocarcinoma previously treated with local therapy (prostatectomy and/or radiotherapy); a rising PSA, defined as two consecutive values >0.2 ng/mL taken ≥3 weeks apart (after primary prostatectomy) or two rising values ≥2.0 ng/mL above the PSA nadir (after primary radiotherapy); a PSADT ≤12 months (using ≥3 PSA values each collected ≥4 weeks apart); plasma testosterone ≥200 ng/dL; and non-metastatic disease (technetium-99 bone scans and computed tomography scans). Key exclusion criteria included inadequate end-organ function; requirement for systemic corticosteroids or immunosuppressive therapies; prior sipuleucel-T; prior ADT (neoadjuvant/adjuvant setting) for ≥6 months or within 6 months of registration; or prior experimental immunotherapies within ≤1 year. All patients provided written informed consent.
Study design and treatment
STAND (NCT01431391) was a multicenter, randomized, open-label, phase II study conducted at 11 US centers. Sixty-eight patients were randomized (using a computer-aided permuted-block scheme) 1:1 to two groups, sipuleucel-T→ADT or ADT→sipuleucel-T ( Supplementary Fig. S1 ). Stratification was based on PSADT (≤3 months vs. >3 to ≤12 months) and primary treatment (prostatectomy vs. radiotherapy vs. both). The study was In the sipuleucel-T→ADT group, patients received three sipuleucel-T intravenous infusions (one every 2 weeks) followed by 12 months of ADT (45 mg leuprolide acetate
[Eligard®] subcutaneous injection every 6 months, for two doses) starting 2 weeks after the third sipuleucel-T infusion. In the ADT→sipuleucel-T group, patients received 12 months of ADT with sipuleucel-T treatment beginning 12 weeks after the first leuprolide injection. For each sipuleucel-T treatment, patients underwent a standard 1.5 to 2.0 blood volume leukapheresis, and received the sipuleucel-T infusion ∼ 3 days later (16) . Blood sampling times are shown in Supplementary Fig. S1 . Final follow-up visits were at months 27 (sipuleucel-T→ADT) and 24 (ADT→sipuleucel-T).
Endpoints
The primary endpoint was PA2024-specific T cell response over time assessed by IFN-γ ELISPOT, a functional assay. PA2024, the immunogen used to manufacture sipuleucel-T is a recombinant fusion protein of PAP and granulocyte-macrophage colony-stimulating factor. 
Assessments
All PA2024-specific and PAP-specific cellular and humoral immune parameters were assessed as previously described (19) . Immune responses were defined as responses >95 th percentile of baseline values. Humoral antigen spread was assessed as previously described (21) .
The protocol-defined PSA recurrence endpoint (22) 
Statistical analyses
For the primary endpoint, 27 patients per arm provide 90% power to detect a 2.5-fold difference in mean PA2024 ELISPOT counts between arms with a two-sided 0.05-level t-test.
Allowing for drop-outs and patients not receiving three sipuleucel-T infusions, the target Humoral antigen spread was statistically analyzed as previously described (21) .
Time-to-event endpoints were analyzed using the Kaplan-Meier method and the log- (16) were compared between studies for secondary antigens: ERAS, KLK2, KRAS, LGALS3, and LGALS8. Pairwise t-tests between data (log 2 difference relative to baseline) from all three trials were performed to evaluate differences between study pairs. As different methods for ELISPOT, T cell proliferation, and humoral responses were used in IMPACT versus STAND, no comparisons were made between studies for these endpoints.
Results
Patients
From September 2011 to August 2012, 68 patients were enrolled: 34 were randomized to each arm (Fig. 1) . All patients received three sipuleucel-T infusions. Almost all received 12 months of ADT (sipuleucel-T→ADT: 33/34; ADT→sipuleucel-T: 32/34). Three men received only 6 months of ADT (two refused the second dose; one changed therapy due to disease progression). Baseline patient characteristics were well balanced between arms (Table 1) .
Immune responses
Analysis of the primary endpoint showed mean PA2024-specific ELISPOT counts 
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There was no correlation of baseline PSA with the magnitude of immune response (by T cell proliferation, IFN-γ ELISPOT, and antibody titers) to both PAP and PA2024, adjusting for treatment arm and visit time point, and treatment by visit interaction (data not shown).
Clinical outcomes
Five (15%) and 11 (32%) PSA recurrence events (protocol-defined analysis) occurred with sipuleucel-T→ADT and ADT→sipuleucel-T, respectively (HR, 2.26, 95% CI, 0.78 to 6.49; P = 0.121); median time-to-PSA progression was not reached in either arm. Median time-to-PSA recurrence (post-hoc definition) from first ADT injection was similar for sipuleucel-T→ADT and ADT→sipuleucel-T (21.8 and 22.6 months, respectively, P = 0.357; Fig. 3A ). PSA recurrence occurred in 71% of patients in each arm after a median follow-up of 26.8 months. No differences were seen between arms in time-to-PSA recurrence after testosterone recovery to ≥175 ng/dL (P = 0.151, Supplementary Fig. S2 ). Of the 48 patients with testosterone recovery, three men (6%; n = 1 sipuleucel-T→ADT; n = 2 ADT→sipuleucel-T) maintained undetectable PSA levels at the end of the study. In particular, two of these patients had prolonged periods of undetectable PSA lasting more than 7.6, and 17.5 months following testosterone recovery.
There were no differences between arms in time-to-testosterone recovery (≥175 ng/dL) ( Supplementary Fig. S3 ), time-to next anti-cancer intervention ( Supplementary Fig. S4 ), or the rate of metastatic progression (Supplementary Material).
Correlative analyses
When combining data across arms, PA2024-specific antibody responses were significantly correlated with a longer time-to-PSA progression (HR, 0.22, 95% CI, 0.08 to 0.67; P = 0.007) (Fig. 3B) . Non-significant trends were observed for PA2024-specific ELISPOT and proliferation responses correlating with longer time-to-PSA recurrence ( 
Safety and tolerability
Sipuleucel-T and ADT were generally tolerated well in both arms, with no new safety signals. AEs were comparable between arms (Supplementary Table S1 ). One patient receiving sipuleucel-T→ADT died from endocarditis and sepsis 7 months after his last sipuleucel-T infusion (considered unrelated to treatment).
Comparison of antigen spread and APC activation with castration-resistant prostate cancer (IMPACT and STAMP)
Following sipuleucel-T administration, humoral antigen spread (IgG responses to secondary antigens: E-RAS, KLK2, K-RAS, LGALS3, and LGALS8) was similar between arms at weeks 2, 6, 12, and months 6, 9, and 12 (all P > 0.25) (data not shown). The magnitude of IgG responses at week 2 to each antigen in STAND (BRPC patients) was significantly higher than in two prior trials (IMPACT [16] and STAMP [20] , mCRPC patients) (P < 0.01 or P ≤ 0.001 for E-RAS, KLK2, K-RAS, LGALS3, and LGALS8; Supplementary Fig. S5 ).
There were no significant differences between arms in sipuleucel-T product parameters ( Supplementary Fig. S6 ). The magnitude of APC activation in STAND was higher than in the pivotal phase III IMPACT trial ( Supplementary Fig. S7 ) (16) . APC activation values were 24%, 43%, and 41% higher on average in STAND versus IMPACT for infusions 1, 2, and 3, respectively (all P < 0.001). The ratio of cumulative APC activation across all infusions in STAND was greater than in IMPACT (ratio of geometric means 1.37, 95% CI, 1.27 to 1.48; P < 0.001). measured time point, was, on average, ~2-fold higher. These results are in broad agreement with the ELISPOT data.
The findings of this study are consistent with preclinical prostate cancer models (7, 12) and a small randomized trial involving men with non-metastatic castrate-resistant prostate cancer, in which survival was longer in patients vaccinated with a PSA-encoding poxviral vaccine prior to second-line ADT (nilutamide) versus those receiving ADT prior to vaccination (13).
In STAND, both sequences resulted in similarly robust and sustained PA2024 cellular responses, PA2024 and PAP humoral responses, and humoral antigen spread to secondary antigens. STAND was also the first trial to demonstrate long-term antitumor immunity lasting for 2 years following sipuleucel-T administration. Sipuleucel-T combined with ADT (in either sequence) was generally well tolerated, with no new emerging toxicities.
Low cellular immune responses to PAP, a self-antigen (25), were not unexpected because activated effector T cells might be expected to concentrate at the tumor site or in lymph nodes, not in the blood compartment from which samples were taken. However, antibodies circulate in the blood, and the observation that sipuleucel-T induced strong PAPspecific humoral responses in both arms of STAND, was an important finding that suggests the ability of sipuleucel-T to break humoral immune tolerance.
Biologically, using cancer immunotherapy earlier is logical because immunotherapy may be more effective when tumor burden is low (26) and the immune system is more intact (27) . As tumors progress, the microenvironment becomes increasingly resistant to an immune response (28) . An exploratory analysis of IMPACT suggested greater survival benefit from sipuleucel-T when given to patients with lower PSA values (29) . Indeed, exploratory analyses in STAND support the notion that immune responses to sipuleucel-T may be greater when administered in less-advanced disease states since cumulative APC activation across the three doses of sipuleucel-T (a measure of product potency and immune activation) was significantly higher in STAND versus IMPACT (16) . While such studies must be regarded as hypothesis-generating, this observation is noteworthy as higher cumulative APC activation has been shown to significantly correlate with survival in mCRPC (19) . With the same measure of caution when comparing across studies, it can be noted that the magnitude of IgG responses to secondary antigens (i.e., antigen spread) was higher in STAND than in mCRPC patients from IMPACT (16) 
